



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOLCP/CGC/2021
10th February 2021

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai - 400 001

Security Code: 524164

Subject: Press Release with respect to Audited Financial Results for the quarter and nine months period ended 31st December 2020.

Dear Sir,

Please find enclosed herewith Press Release with respect to Audited Financial Results for the quarter and nine months ended 31st December 2020.

The Press Release is also available on the website of the Company i.e. www.iolcp.com.

This is for your information & record.

Thanking You,

Yours faithfully,

For IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh

AVP & Company Secretary




Press Release

 10th February, 2021, Ludhiana

**PBT up by 15% to Rs.465 crores for nine months ended DEC 2020
 PAT up by 36% to Rs.369 crores for nine months ended DEC 2020**

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals today posted strong performance in the nine months ending December 2020.

Nine months ended December 2020 vis a vis Nine months ended December 2019


Particulars	Nine months ended		Rs Crore
	31.12.2020	31.12.2019	%age change
Total income from operations	1525	1464	4%
EBIDTA	499	448	11%
Net Profit before Tax	465	403	15%
Net Profit after Tax	369	271	36%
EPS	63.45	47.64	33%

Quarter ended December 2020 vis a vis Quarter ended December 2019

Particulars	Quarter ended		Rs Crore
	31.12.2020	31.12.2019	%age change
Total income from operations	521	515	1%
EBIDTA	165	163	1%
Net Profit before Tax	154	151	2%
Net Profit after Tax	115	98	17%
EPS	19.54	17.22	13%

Mr Vijay Garg, Joint Managing Director said " During the nine months period the Company has performed well and the operational efficiency of the Company has improved. We are delighted to inform that the Chemical division of the Company has also performed better during this period. The PAT in the nine months period exceeded the PAT of last full year. Delivering Quality and regulatory Compliances remain the priority of the Company."

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange (Code: IOLCP) and Bombay Stock Exchange (Code: 524164) is one of the leading APIs/ bulk drugs Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.